S&P TSX Capped Composite...

US Dollar vs CAD

Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

Get Started

INDP Indaptus Therapeutics Inc

0.92

-0.01 (-1.08%)

Jan 24 2025 - Closed

Delayed by 15 minutes

Form D - Notice of Exempt Offering of Securities

Indaptus Therapeutics (NASDAQ:INDP)
Historical Stock Chart
From Dec 2024 to Jan 2025

Click Here for more Indaptus Therapeutics Charts.

Indaptus Therapeutics (NASDAQ:INDP)
Historical Stock Chart
From Jan 2024 to Jan 2025

Click Here for more Indaptus Therapeutics Charts.

Indaptus Therapeutics Inc News

Form D - Notice of Exempt Offering of Securities
Wednesday 22 January 2025 (4 days ago) • Edgar (US Regulatory)

Form 8-K - Current report
Tuesday 14 January 2025 (2 weeks ago) • Edgar (US Regulatory)

Indaptus Therapeutics, Inc. Announces $2.25 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Monday 13 January 2025 (2 weeks ago) • GlobeNewswire Inc.

Indaptus Therapeutics Provides Year-End Review and Outlook for 2025
Wednesday 8 January 2025 (3 weeks ago) • GlobeNewswire Inc.

Form S-1 - General form for registration of securities under the Securities Act of 1933
Monday 23 December 2024 (1 month ago) • Edgar (US Regulatory)

Form 8-K - Current report
Friday 22 November 2024 (2 months ago) • Edgar (US Regulatory)

Form 424B5 - Prospectus [Rule 424(b)(5)]
Friday 22 November 2024 (2 months ago) • Edgar (US Regulatory)

Indaptus Therapeutics, Inc. Announces $2.135 Million Registered Direct Offering and Concurrent Private Placement
Friday 22 November 2024 (2 months ago) • GlobeNewswire Inc.

Form 8-K - Current report
Tuesday 12 November 2024 (2 months ago) • Edgar (US Regulatory)

Indaptus Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Tuesday 12 November 2024 (2 months ago) • GlobeNewswire Inc.

Indaptus Therapeutics’ Pioneering Research on Novel Immunotherapy Approach Published in Peer-Reviewed Frontiers in Immunology
Monday 11 November 2024 (3 months ago) • GlobeNewswire Inc.

Indaptus Therapeutics Presents Encouraging Interim Safety Data from Phase 1 Clinical Trial of Decoy20 at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting
Thursday 7 November 2024 (3 months ago) • GlobeNewswire Inc.

More Indaptus Therapeutics Inc News Articles

Kraig Biocraft Laborator... (QB)

Anavex Life Sciences

Bioelectronics (PK)

Decentral Life (PK)

Northwest Biotherapeutics (QB)

Good Vibrations Shoes (PK)

Fannie Mae (QB)

Elite Pharmaceuticals (QB)

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions